{"entity":{"id":"laboratory-certification-test-authorization","kind":"term","name":"Laboratory certification and test authorization","aka":["Clinical Laboratory Improvement Amendments","CLIA laboratory certification","CLIA certification","laboratory quality versus test authorization"],"tldr":"Laboratory certification addresses the laboratory and its testing quality. Product authorization and evidence that a particular test use helps patients answer separate questions.","summary":"The U.S. Clinical Laboratory Improvement Amendments program sets laboratory-quality requirements for testing human specimens. CMS distinguishes analytical oversight under that program from clinical validity, which concerns what a result means for a clinical condition. A research-use label describes intended purpose; a laboratory-developed-test description concerns how and where a test is developed and used. FDA product authorization concerns a specified product and intended use. These descriptions can coexist and do not form one universal ladder of clinical usefulness or payment.","asOf":"2026-11-13","links":[{"label":"CMS: Clinical Laboratory Improvement Amendments","url":"https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments"},{"label":"CMS: CLIA analytical oversight and clinical validity (2013 FAQ; historical FDA discussion not used)","url":"https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf"},{"label":"FDA: current laboratory-developed-test rule notice","url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests"},{"label":"FDA: research-use-only and investigational-use-only IVD guidance","url":"https://www.fda.gov/media/87374/download"},{"label":"FDA: companion diagnostics","url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics"},{"label":"FDA: registration and listing do not establish authorization","url":"https://www.fda.gov/medical-devices/device-registration-and-listing/important-reminders-about-registration-and-listing"},{"label":"ASCO/CAP: ER and PR testing recommendations (2020)","url":"https://www.cap.org/wp-content/uploads/documents/erpgr_summaryrecommendations.pdf"},{"label":"FDA: companion diagnostic labeling for a group of oncology products (April 2020)","url":"https://www.fda.gov/media/120340/download"}],"tags":[],"related":["research-use-only","fda-ldt-rule","analytical-vs-clinical-validation","companion-diagnostic","companion-diagnostic-term"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The CMS FAQ is used here for the analytical-oversight versus clinical-validity distinction, not its historical discussion of FDA authority over laboratory-developed tests. Current procedural history is retained in the separate FDA LDT-rule record.","An entry in FDA establishment registration or device listing does not itself mean that the facility or device is approved, cleared or authorized. Registration and product authorization are separate claims.","Three examples separate intended uses. Validated ER immunohistochemistry in invasive breast cancer, with appropriate tissue handling, tumour-nucleus scoring and controls, has a marker-specific pathology and endocrine-treatment assessment role; it does not validate a new RNA score as a substitute. In a wholly fictional second example, assay T version 1 detects alteration M in fixed tumour tissue under rule R, and Drug A requires exactly that result in setting S. The stipulated match supplies that requirement within the exercise, without promising benefit; another specimen, result type or setting needs evidence for the changed use. A third fictional score Q combines RNA, spatial neighbourhoods and a derived culture response to propose Drug A. Reproducibility and biological support can justify research, but do not establish that Q-guided care improves outcomes against an appropriate comparator. A laboratory certificate does not supply that missing evidence. Useful research and an established clinical use can appear on different parts of one report."],"category":"Regulation & policy"},"route":"/terms/laboratory-certification-test-authorization/","neighbours":{"term":[{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/"},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/"},{"id":"fda-ldt-rule","kind":"term","name":"FDA laboratory-developed test (LDT) rule","route":"/terms/fda-ldt-rule/"},{"id":"research-use-only","kind":"term","name":"Research use only (RUO)","route":"/terms/research-use-only/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}]}}